Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.PHVS stock is gaining positive traction. Check the market position here.HAE is a rare genetic disorder that causes recurrent, severe swelling in the skin, face, limbs, and internal organs, including the airway and gastrointestinal tract.The study enrolled a total of 134 participants that evaluated the orally administered deucrictiba ...